MA35129B1 - Traitement du myélome multiple - Google Patents

Traitement du myélome multiple

Info

Publication number
MA35129B1
MA35129B1 MA36455A MA36455A MA35129B1 MA 35129 B1 MA35129 B1 MA 35129B1 MA 36455 A MA36455 A MA 36455A MA 36455 A MA36455 A MA 36455A MA 35129 B1 MA35129 B1 MA 35129B1
Authority
MA
Morocco
Prior art keywords
multiple myeloma
treatment
subject
prevalence
phenotype
Prior art date
Application number
MA36455A
Other languages
English (en)
Inventor
Christopher John Burns
Andrew Spencer
Katherine Anne Monaghan
Original Assignee
Ym Biosciences Australia Pty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47107683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35129(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ym Biosciences Australia Pty filed Critical Ym Biosciences Australia Pty
Publication of MA35129B1 publication Critical patent/MA35129B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une méthode de traitement d'un sujet présentant un myélome multiple à un stade caractérisé par une augmentation de la prévalence de cellules mm qui (1) ne réagissent pas à l'il-6 et/ou (2) ont un phénotype cd45, consistant à administrer au sujet une quantité de composé représenté par la formule ib.
MA36455A 2011-05-02 2013-11-20 Traitement du myélome multiple MA35129B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481425P 2011-05-02 2011-05-02
PCT/AU2012/000462 WO2012149602A1 (fr) 2011-05-02 2012-05-01 Traitement du myélome multiple

Publications (1)

Publication Number Publication Date
MA35129B1 true MA35129B1 (fr) 2014-05-02

Family

ID=47107683

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36455A MA35129B1 (fr) 2011-05-02 2013-11-20 Traitement du myélome multiple

Country Status (21)

Country Link
US (1) US20140171433A1 (fr)
EP (1) EP2704722A4 (fr)
JP (1) JP2014514337A (fr)
KR (1) KR20140081757A (fr)
CN (1) CN103533939A (fr)
AP (1) AP2013007281A0 (fr)
AU (1) AU2012250491A1 (fr)
BR (1) BR112013028420A2 (fr)
CA (1) CA2834414A1 (fr)
CL (1) CL2013003143A1 (fr)
CO (1) CO6900134A2 (fr)
EA (1) EA201391591A1 (fr)
IL (1) IL228981A0 (fr)
MA (1) MA35129B1 (fr)
MD (1) MD20130089A2 (fr)
MX (1) MX2013012785A (fr)
PE (1) PE20140750A1 (fr)
PH (1) PH12013502144A1 (fr)
SG (1) SG194212A1 (fr)
WO (1) WO2012149602A1 (fr)
ZA (1) ZA201308918B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
US10363260B2 (en) 2014-05-28 2019-07-30 Oncotracker, Inc. Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids
TWI681954B (zh) * 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
KR102524920B1 (ko) 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN105837515B (zh) * 2016-04-06 2018-08-03 中国药科大学 一种JAK抑制剂Momelotinib的制备方法
CN106075046A (zh) * 2016-07-31 2016-11-09 孙书芳 一种治疗肝肾阴虚型多发性骨髓瘤的中药
US10487321B2 (en) * 2016-09-29 2019-11-26 PZM Diagnostics, LLC Method of extraction of genomic DNA for molecular diagnostics and application
WO2019055930A1 (fr) * 2017-09-15 2019-03-21 University Of Iowa Research Foundation Procédés d'identification de cellules initiatrices de tumeur de myélome et thérapie ciblée
CN109045040A (zh) * 2018-03-12 2018-12-21 首都医科大学附属北京天坛医院 Cyt387用于制备治疗神经胶质瘤的药物的应用
CN111100076A (zh) * 2019-12-30 2020-05-05 武汉九州钰民医药科技有限公司 Jak抑制剂莫美洛替尼的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1984651A (zh) * 2004-05-05 2007-06-20 细胞基因公司 使用选择性细胞因子抑制药治疗和控制癌症和其它疾病的方法和组合物
WO2008064866A1 (fr) * 2006-11-27 2008-06-05 Ares Trading S.A. Traitement du myélome multiple
HUE029188T2 (en) * 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use

Also Published As

Publication number Publication date
WO2012149602A1 (fr) 2012-11-08
CN103533939A (zh) 2014-01-22
IL228981A0 (en) 2013-12-31
EP2704722A4 (fr) 2014-11-05
BR112013028420A2 (pt) 2017-01-24
CL2013003143A1 (es) 2014-07-04
EP2704722A1 (fr) 2014-03-12
AP2013007281A0 (en) 2013-11-30
SG194212A1 (en) 2013-11-29
CO6900134A2 (es) 2014-03-20
PE20140750A1 (es) 2014-07-06
JP2014514337A (ja) 2014-06-19
MX2013012785A (es) 2014-05-28
EA201391591A1 (ru) 2014-12-30
KR20140081757A (ko) 2014-07-01
PH12013502144A1 (en) 2017-10-25
MD20130089A2 (ro) 2014-05-31
AU2012250491A1 (en) 2013-05-02
US20140171433A1 (en) 2014-06-19
ZA201308918B (en) 2014-08-27
CA2834414A1 (fr) 2012-11-08

Similar Documents

Publication Publication Date Title
EA201592223A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA SERPINAl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CL2022001256A1 (es) Métodos y composiciones para tratar un trastorno asociado con el angiotensinogeno agt
MD4685B1 (ro) Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2
MD20130089A2 (ro) Metodă de tratament al mielomului multiplu
EA201692370A1 (ru) КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
EA201991412A1 (ru) Ингибиторы поли(адф-рибоза)полимеразы (parp)
EA201890373A1 (ru) Пиридиновые соединения, пригодные для борьбы с фитопатогенными грибами
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201200917A1 (ru) Пролекарства ингибиторов плазменного калликреина
MA38959A1 (fr) Modulateurs du facteur b du complément
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
EA200970512A1 (ru) Лечение по поводу множественной миеломы
EA201791353A1 (ru) СОЕДИНЕНИЯ ИЗОКСАЗОЛГИДРОКСАМИНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LpxC
EA201891811A1 (ru) Фунгицидные композиции
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
EA201501111A1 (ru) Замещенные n-(тетразол-5-ил)- и n-(триазол-5-ил)арилкарбоксамидные соединения и их применение в качестве гербицидов
MX2020013269A (es) Inhibidores de la vía de respuesta al estrés integrada.
MA35615B1 (fr) Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf
MA44836A (fr) Procédés de traitement du syndrome polykystique des reins
MX2022002443A (es) Compuestos inhibidores de perk.
EA201590379A1 (ru) Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа